Neurocrine Biosciences (NBIX) EV to FCF (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported EV to FCF for 17 consecutive years, with 130.12 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to FCF rose 1.56% year-over-year to 130.12; the trailing twelve-month figure through Jun 2026 stood at 19.23 (down 11.36% YoY), and the FY2025 full-year result was 16.99, down 24.24% from the prior year.
• EV to FCF improved to 130.12 in Q2 2026 per NBIX's latest filing, from 87.32 in the prior quarter.
• Across five years, EV to FCF topped out at 242.49 in Q2 2024 and bottomed at 172.31 in Q1 2022.
• Historically, EV to FCF has averaged 71.56 across 5 years, with a median of 72.08 in 2024.
• The sharpest annual moves came in 2022 and 2024: EV to FCF sank 271.56% in 2022, then surged 409.33% in 2024.
• Over 5 years, EV to FCF stood at 74.57 in 2022, then surged by 35.87% to 101.31 in 2023, then sank by 47.58% to 53.11 in 2024, then sank by 38.73% to 32.54 in 2025, then surged by 299.88% to 130.12 in 2026.
• According to Business Quant data, EV to FCF over the past three periods registered 130.12, 87.32, and 32.54 for Q2 2026, Q1 2026, and Q4 2025 respectively.